For a long time in the past, the prognosis of advanced lung cancer was very poor, with the 5-year survival rate often below 5%. However, with the widespread use of targeted drugs, immune drugs and local treatments such as radiotherapy, the survival period of lung cancer has now been significantly extended and the quality of life has been significantly improved. If 5-year survival is taken as the standard for clinical cure, there are many advanced stage patients who can achieve a survival of more than 5 years. In ALK-positive patients with advanced non-small cell lung cancer, the median progression-free survival of ALK-positive non-small cell lung cancer was 34.8 months in the ALEX clinical study using the second-generation ALK-targeting drug aletinib in the first line, with a 5-year survival rate of 62.5%, and the ALK fusion mutation was also called a veritable “diamond “diamond” mutations. In patients with EGFR-positive advanced non-small cell lung cancer, the median progression-free survival was 18.9 months and the 5-year expected survival rate was 31.1% in the FLAURA study with first-line use of the third-generation EGFR-targeting agent, oseltinib. In advanced non-small cell lung cancer, the 5-year survival rate for second-line immunotherapy with pabolizumab monotherapy was 23.2%, with a 5-year survival rate of 29.6% for patients with high PD-L1 expression (TPS ≥ 50%) and 15.7% for patients with PD-L1 (1% ≤ TPS ≤ 49%). Among patients with high PD-L1 expression (TPS ≥ 50%), the 5-year survival rate reached 31.9% with first-line pablizumab. Among patients with advanced non-small cell oligometastases, the median survival of patients who received systemic therapy and local treatment of oligometastases was 41.2 months. 5-year survival reached 29.4%. Moreover, most of these patients had not received targeted and immunotherapy. Patients with inoperable stage III (locally advanced) lung cancer who had stable disease after radical concurrent radiotherapy had a median survival of 47.5 months and a 5-year survival rate of 42.9% in the PACIFIC study who received maintenance therapy with dulvalizumab. Overall, the survival of advanced stage patients beyond 5 years requires multidisciplinary local treatment including radiotherapy department, in addition to factors such as their own relatively good physical condition, the use of targeted drugs with gene mutations such as EGFR and ALK, and receiving effective immunotherapy. Local treatment together with systemic treatment, long-term treatment of advanced lung cancer is no longer a dream.